David E. Lazar - 18 Dec 2025 Form 4 Insider Report for KALA BIO, Inc. (KALA)

Role
Chief Executive Officer, Director
Signature
/s/ David E. Lazar
Issuer symbol
KALA
Transactions as of
18 Dec 2025
Net transactions value
$0
Form type
4
Filing time
22 Dec 2025, 17:18:14 UTC
Previous filing
26 Nov 2025
Next filing
23 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lazar David E. Chief Executive Officer, Director 44, TOWER 100, THE TOWERS, WINSTON CHURCHILL, PAITILLA, PANAMA CITY, PANAMA /s/ David E. Lazar 22 Dec 2025 0001932843

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding KALA Common Stock 0 18 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALA Convertible Loan Other -368,614 -100% 0 18 Dec 2025 Common Stock 368,614 $1.02 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares of common stock are beneficially owned.
F2 Not applicable.
F3 On November 9, 2025, the Reporting Person, as "Lender", entered into a Convertible Loan Agreement (the "Agreement") with Issuer pursuant to which Lender agreed to loan the Issuer up to an amount of $375,000. Pursuant to the Agreement, the Lender had the right in its discretion at any time prior to the full repayment of the Loan Amount (as defined in the Agreement) to the Lender, to convert all or any of the then outstanding and unpaid portion of the Loan Amount into Issuer's common stock at the "Conversion Price" (as defined in the Agreement). On December 18, 2025, the Issuer repaid the full Loan Amount to the Reporting Person in cash.